Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop
Source: www.businesswire.com
Gilead Sciences Inc. has entered into a strategic collaboration with insitro to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Insitro is a data-driven drug discovery and development company that uses machine learning to transform the way that drugs are discovered and delivered to patients. Under the terms of the three-year collaboration, insitro’s proprietary platform (insitro Human) will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease.
